Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImExHSASX:IME 50 EBITDA Margin % is 7.79% as of Dec. 2025. GuruFocus rates ASX:IME with a GF Score™ of 50/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, ImExHS ranks worse than 56.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ImExHS's EBITDA for the
six
months ended in Dec. 2025 was A$1.19 Mil. ImExHS's Revenue for the
six
months ended in Dec. 2025 was A$15.32 Mil. Therefore, ImExHS's EBITDA margin for the quarter that ended in Dec. 2025 was 7.79%.
ImExHS (ASX:IME) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ImExHS EBITDA Margin % Related Terms
ImExHS EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ImExHS's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IME vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, ImExHS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImExHS EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ImExHS's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ImExHS's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImExHS (ASX:IME) has a EBITDA Margin % of 7.79% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ImExHS and its competitors. According to the industry distribution chart, ImExHS ranks #115 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 56.7%.
Is ImExHS's EBITDA Margin % too high?
ImExHS's current EBITDA Margin % is 7.79%. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. ImExHS's value of 7.79% is 55.8% above this industry median. Based on the distribution chart, ImExHS ranks #115 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, ImExHS has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImExHS's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, ImExHS ranks #115 out of 203 companies for EBITDA Margin %. This places ImExHS in the lower half of its industry. The industry median EBITDA Margin % is 5.00. ImExHS's value of 7.79% is 55.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImExHS's current EBITDA Margin % of 7.79% is 55.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ImExHS and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImExHS's current EBITDA Margin % is 7.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImExHS stock overvalued right now?
Based on GuruFocus' analysis, ImExHS (ASX:IME) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.31 — trading 39.2% below its estimated fair value. The current EBITDA Margin % is 7.79% and 55.8% above the Medical Diagnostics & Research industry median of 5.00. ImExHS's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ImExHS (ASX:IME), the current EBITDA Margin % is 7.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImExHS (ASX:IME) Overvalued in 2026?
Based on GuruFocus' analysis, ImExHS stock appears to be undervalued.
The current stock price of A$0.31 is trading 39.2% below its estimated GF Value™ of A$0.51.
GuruFocus considers ImExHS to be Possible Value Trap.
Key valuation signals for ASX:IME:
EBITDA Margin %: 7.79%
GF Value™: A$0.51 vs. price of A$0.31 (39.2% below fair value)
Industry Position: 55.8% above the Medical Diagnostics & Research median (#115 of 203)
No single metric tells the full story. See the ASX:IME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImExHS Ltd is a healthcare technology company engaged in the provision of medical imaging software and radiology services. The company develops and delivers enterprise imaging solutions, including radiology information systems and picture archiving and communication systems, as well as provides diagnostic imaging and teleradiology services to healthcare institutions. The company operates through two reportable segments: Software, which focuses on the development and sale of imaging systems and platforms, and Radiology Services, which provides diagnostic and teleradiology services to hospitals and medical facilities. It generates the majority of its revenue from the Radiology segment.
50GF Score
Get the complete analysis for ASX:IME
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IME has been successfully added to your 
